AH Equity Partners Bio I, L.L.C. - Oct 10, 2024 Form 3 Insider Report for Camp4 Therapeutics Corp (CAMP)

Role: 10%+ Owner
Signature: AH Bio Fund I, L.P. for itself and as nominee for AH Bio Fund I-B, L.P., By: AH Equity Partners Bio I, L.L.C., its General Partner, By /s/ Scott Kupor, Authorized Signatory
Stock symbol: CAMP
Transactions as of: Oct 10, 2024
Transactions value $: $0
Form type: 3
Date filed: 10/10/2024, 09:18 PM
Next filing: Oct 17, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CAMP	Series A Prime Preferred Stock							Oct 10, 2024	Common Stock	1.34M		By AH Bio Fund I, L.P., as nominee	F1, F2
holding	CAMP	Series B Preferred Stock							Oct 10, 2024	Common Stock	60.6K		By AH Bio Fund I, L.P., as nominee	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering, the Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.
F2	These shares are held of record by AH Bio Fund I, L.P. ("AH Bio I") for itself and as nominee for AH Bio Fund I-B, L.P. (collectively, the "AH Bio I Entities"). AH Equity Partners Bio I, L.L.C. ("AH EP Bio I"), the general partner of the AH Bio I Entities, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.

Content

Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering, the Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.

These shares are held of record by AH Bio Fund I, L.P. ("AH Bio I") for itself and as nominee for AH Bio Fund I-B, L.P. (collectively, the "AH Bio I Entities"). AH Equity Partners Bio I, L.L.C. ("AH EP Bio I"), the general partner of the AH Bio I Entities, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.